Diagnosis of gastric cancer by measuring the urinary porphyrins after oral administration of 5-aminolevulinic acid (ALA).
Not Applicable
- Conditions
- Gastric cancer
- Registration Number
- JPRN-UMIN000032048
- Lead Sponsor
- Osaka Police Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with severe anamnesis (Malignant hypertension. With severe congestive heart failure. Severe liver failure. Myocardial infarction within 3 months. End-stage cirrhosis. Poorly controlled diabetes. Severe pulmonary fibrosis. Interstitial pneumonia activity) 2) Patients who are able to orally intake foods. 3) Patients with porphyria or hypersensitivity to porphyrins allergy 4) Cancer patients within 5 years after treatment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The urinary and serum levels of porphyrins (5-ALA, uroporphyrin I and III, coproporphyrin I and III, protoporphyrin IX) after oral administration of 5-ALA in gastric cancer patients before and after gastrectomy and non-cancer patients.
- Secondary Outcome Measures
Name Time Method